Eversight announced it is the first eye bank to prepare preloaded Descemet membrane endothelial keratoplasty (DMEK) tissue in the Melles DORC tube, offering corneal surgeons more preloaded tissue options that further streamline surgeries and reduce cost, according to a company news release.
“The more time ophthalmologists can spend focused on patients and procedures, the better. As preference for DORC grew, Eversight saw a viable opportunity to further simplify preoperative preparation,” Michael Titus, Vice President of Clinical Operations, Eversight, said in the news release. “The preloaded DORC tube arrives onsite ready for the operating room. This natural evolution of Eversight’s tissue services demonstrates our continued work to address procedural needs and improve patients’ lives.”
The DORC injector demonstrates low endothelial cell count loss1 and is the instrument of choice for many eye surgeons. Developed by Gerrit R.J. Melles, MD, PhD, and the Dutch Ophthalmic Research Center (DORC), the curved glass tube provides an ergonomic injection angle and its long, tapered end can advance further into the anterior chamber for smooth, precise delivery of the donor corneal graft. The DORC tube requires a small 2.4mm incision that may facilitate sutureless procedures, improve healing and enable surgeons to perform multiple procedures during a single case.
“With Eversight’s new preloaded DMEK option, there is virtually nothing that I or my clinical staff have to do to prepare the tissue,” said Parag A. Majmudar, MD, Chicago Cornea Consultants, a DORC user since 2013. “There is also no need to alter the surgical procedure in any way, such as enlarging the incision. Preloaded DORC creates a seamless DMEK insertion experience that minimizes complications for fellows and seasoned surgeons alike.”
1 Droutsas K, Lazaridis A, Kymionis GD, et al. Comparison of endothelial cell loss and complications following DMEK with the use of three different graft injectors. Eye (Lond). 2018;32(1):19–25. doi:10.1038/eye.2017.237